Fecal Microbiota Transplantation (FMT) to Decolonize Antibiotic - Resistant Bacteria (ARB) - New Protocol (STOP-ARB2)
Fecal Microbiota Transplantation to Eradicate Antibiotic-resistance Bacteria From the Gastrointestinal Tract of Patients at High Risk of Infection and/or to Cut Off the Spread of Bacteria With Dangerous Mechanisms of Antibiotic Resistance
Sponsor: Human Biome Institute S.A.
Listed as NCT06156956, this NA trial focuses on Antimicrobial Drug Resistance and Drug Resistance, Bacterial and remains ongoing. Sponsored by Human Biome Institute S.A., it has been updated 5 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2025 — Feb 2026 [monthly]
Recruiting NA
-
Sep 2024 — Sep 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jan 2024 — Jul 2024 [monthly]
Recruiting NA
First recorded
Oct 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Human Biome Institute S.A.
For direct contact, visit the study record on ClinicalTrials.gov .